LabCompass

Vidya Arole

Computer Science · The Ohio State University

OpenAlex ORCID
Early career · publishing since 2018
AI in cancer detectionRadiomics and Machine Learning in Medical ImagingCancer Immunotherapy and BiomarkersColorectal Cancer Surgical TreatmentsBladder and Urothelial Cancer Treatments

Publications

16

Citations

186

Est. group size

—

Recurring co-author estimate

Active years

9

Publishing since 2018

Research summary
AI-generated

Vidya Arole's work spans areas of pathology and cancer research, including the use of artificial intelligence and machine learning tools to help analyze medical images and predict cancer outcomes, as well as biomarker studies in cancers such as colorectal and bladder cancer. Some publications also touch on kidney disease (glomerulonephritis) linked to liver conditions. This research is largely based on studying patient tissue samples and clinical data to improve diagnosis and treatment decisions.

AI-assisted cancer diagnosisMedical imaging analysis (radiomics)Cancer biomarkersColorectal and urothelial cancer treatmentKidney and liver disease pathology

Publication output has been low and irregular over the past decade, with a peak in 2018 and generally fewer than two papers per year since.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence
Publications per year over the last 10 years — averaging 1.2/year recently
172018: 5 publications5182019: 3 publications192020: 1 publication202021: 1 publication212022: 2 publications222023: 1 publication232024: 1 publication24252026: 2 publications26
Recent publications
Publishes in
  • PLoS ONE×2
  • Scientific Reports×2
  • Journal of Clinical Oncology×2
  • Breast Cancer Research and Treatment×1
  • BMC Cancer×1
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 19, 2026.

Claim or correct this profile